Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Osimertinib in EGFR-mutant NSCLC
NCT02954523Phase 2Terminated
- Sponsor
- Chul Kim
- Start
- Oct 2016
- Primary completion
- Aug 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in non-small cell lung cancer (NSCLC), sponsored by Chul Kim. Started Oct 2016; status: terminated.
02
Drugs
dasatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02954523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954523.